Iovance Biotherapeutics (IOVA) Non-Current Deferred Tax Liability (2023 - 2026)

Iovance Biotherapeutics (IOVA) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $30.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 4.22% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at $30.6 million (down 4.22% YoY), while the FY2025 annual figure was $31.8 million, down 1.51% from the prior year.
• Non-Current Deferred Tax Liability fell to $30.6 million in Q1 2026 per IOVA's latest filing, from $31.8 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $34.7 million in Q2 2025 and bottomed at $17.3 million in Q4 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $28.2 million across 4 years, with a median of $31.7 million in 2025.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability jumped 86.29% — and 2026, when it dropped 4.22%.
• Iovance Biotherapeutics' Non-Current Deferred Tax Liability stood at $17.3 million in 2023, then soared by 86.29% to $32.3 million in 2024, then dropped by 1.51% to $31.8 million in 2025, then retreated by 3.81% to $30.6 million in 2026.
• Business Quant data shows IOVA's Non-Current Deferred Tax Liability at $30.6 million in Q1 2026, $31.8 million in Q4 2025, and $31.7 million in Q3 2025.